Under the terms of the agreement, Centrus will continue to perform engineering and testing work to preserve and advance U.S.-origin uranium enrichment technology to support future national security and energy security needs. The contract totals approximately $32.3 million and runs through September 30, 2016.
Gross profit of $69 million, compared to losses in 2014 and 2013; Net loss of $187.4 million following non-cash charge of $137.2 million for the impairment of excess reorganization value; Positive cash flow from operations increases year-end cash balance to $234 million
Centrus will broadcast its quarterly conference call over the Internet on March 22, 2016, at 8:30 a.m. ET. The Company will release its year-end earnings report for its fiscal 2015 after the close of markets on Monday, March 21.
Centrifuge research, engineering and testing work will continue in Oak Ridge, Tenn.; Ohio centrifuge cascade to be demobilized after successful three-year demonstration; Centrus preserving NRC license and options for future use of Ohio facility
NYSE MKT has accepted Centrus’ plan to regain compliance with the exchange’s continued listing standards, and the company’s common stock will continue to be traded on the exchange, subject to ongoing monitoring by the exchange and the Company’s compliance with all other applicable NYSE MKT requirements.
Members of the board have advised U.S. presidents of both parties, served at the highest levels of government and industry, and have deep subject-matter expertise. The diverse membership reflects a broad consensus about the importance of maintaining U.S. leadership in uranium enrichment and nuclear power.
Centrus and TENEX have reached agreement to modify the terms of the long-term supply contract the two companies signed in 2011 and to extend their contractual relationship through 2026.